Design of a biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD Phase 2 trials

被引：0
|
作者：
Ronco, L. [1 ]
Cadavid, D. [1 ]
Chang, A. [1 ]
Mellion, M. [1 ]
Rojas, A. [1 ]
Shen, N. [1 ]
Tawil, R. [2 ]
Tapscott, S. [3 ]
Wang, L. [3 ]
Wallace, O. [1 ]
机构：
[1] Fulcrum Therapeut, Cambridge, MA USA
[2] Univ Rochester, Med Center
[3] Univ Washington, Seattle, WA 98195 USA
来源：
NEUROMUSCULAR DISORDERS | 2019年 / 29卷
关键词：
D O I：
10.1016/j.nmd.2019.06.076
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.47
引用
收藏
页码：S54 / S55
页数：2
相关论文
共 50 条
  • [1] A biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD Phase 2 trials
    Ronco, L.
    Wagner, K.
    Cadavid, D.
    Chang, A.
    Mellion, M.
    Robertson, A.
    Raines, S.
    Chadchankar, J.
    Rojas, A.
    Shieh, P.
    Shen, N.
    Statland, J.
    Tapscott, S.
    Tawil, R.
    van Engelen, B.
    Wang, L.
    Johnson, N.
    Wallace, O.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S113 - S113
  • [2] A Biomarker of DUX4 Activity to Evaluate losmapimod Treatment Effect in FSHD Phase 2 Trials
    Ronco, Lucienne
    Shieh, Perry
    Tawil, Alrabi
    Wagner, Kathryn
    Statland, Jeffrey
    Raines, Shane
    Shen, Ning
    Chadchankar, Jayashree
    Chang, Aaron
    Robertson, Alan
    Cadavid, Diego
    Mellion, Michelle
    Rojas, Alejandro
    Wallace, Owen
    van Engelen, Baziel
    Wang, Leo
    Johnson, Nicholas
    NEUROLOGY, 2020, 94 (15)
  • [3] DUX4 Optimization for the Development of an Antibodyoligonueleoti.de Conjugate (AOC) for the Treatment of FSHD
    Malecova, Barbora
    Sala, David
    Melikian, Garineh Mary
    Erdogan, Gulin
    Johns, Rachel
    Young, Joanne
    Ventre, Erwann
    Gatto, Sole
    Onorato, Matthew
    Pavlicek, Adam
    Kiraly, Orsolya
    Koegler, Martin
    Levin, Arthur A.
    Hadwiger, Philipp
    Flanagan, Mike
    Stahl, Mark
    NEUROLOGY, 2022, 98 (18)
  • [4] Reachable workspace to evaluate efficacy of losmapimod in subjects with FSHD in two phase 2 studies
    Tawil, R.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S104 - S104
  • [5] SYSTEMIC EFFECT OF EXPRESSION OF THE FSHD-ASSOCIATED DUX4 GENE IN MESENCHYMAL STEM CELLS
    Serbina, O.
    Kiseleva, E.
    Karpukhina, A.
    Vassetzky, Y.
    CYTOTHERAPY, 2022, 24 (05) : S80 - S81
  • [6] PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level
    Banerji, Christopher R. S.
    Zammit, Peter S.
    HUMAN MOLECULAR GENETICS, 2019, 28 (13) : 2224 - 2236
  • [7] Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2
    Richard JLF Lemmers
    Patrick J van der Vliet
    Judit Balog
    Jelle J Goeman
    Wibowo Arindrarto
    Yvonne D Krom
    Kirsten R Straasheijm
    Rashmie D Debipersad
    Gizem Özel
    Janet Sowden
    Lauren Snider
    Karlien Mul
    Sabrina Sacconi
    Baziel van Engelen
    Stephen J Tapscott
    Rabi Tawil
    Silvère M van der Maarel
    European Journal of Human Genetics, 2018, 26 : 94 - 106
  • [8] Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2
    Lemmers, Richard J. L. F.
    van der Vliet, Patrick J.
    Balog, Judit
    Goeman, Jelle J.
    Arindrarto, Wibowo
    Krom, Yvonne D.
    Straasheijm, Kirsten R.
    Debipersad, Rashmie D.
    Ozel, Gizem
    Sowden, Janet
    Snider, Lauren
    Mul, Karlien
    Sacconi, Sabrina
    van Engelen, Baziel
    Tapscott, Stephen J.
    Tawil, Rabi
    van der Maarel, Silvere M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 (01) : 94 - 106
  • [9] Whole body MRI quantitative muscle analysis to evaluate efficacy of Losmapimod in a phase 2 placebo-controlled study in subjects with FSHD (ReDUX4)
    Mellion, M.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S150 - S150
  • [10] Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression
    Lu-Nguyen, Ngoc
    Dickson, George
    Malerba, Alberto
    Popplewell, Linda
    BIOMEDICINES, 2022, 10 (07)
12345